Search results
Results from the WOW.Com Content Network
Ezetimibe works by decreasing cholesterol absorption in the intestines. [5] Ezetimibe was approved for medical use in the United States in 2002. [4] It is available as a generic medication. [5] In 2022, it was the 79th most commonly prescribed medication in the United States, with more than 8 million prescriptions. [11] [12]
On rare occasions, ezetimibe may cause cholecystitis, pancreatitis, elevation of serum transaminase level and rhabdomyolysis. As hepatic impairment hinders the rate of ezetimibe metabolism by the liver, ezetimibe is not recommended in individuals with moderate or severe hepatic insufficiency due to prolonged systemic exposure to the drug. [ 19 ]
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]
When there is dysfunction at this transitional joint, it can cause referred pain to the lower back, hip, abdominal, and/or groin/testicular/labia area, Dr. Megan Daley, PT, DPT, Cert Dn, CF-L1 ...
FYI, what causes back pain in females is largely the same as in males. But the causes of lower back pain in women can also include pregnancy and medical conditions that affect women, like ...
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
What one nurse learned about humanity amidst the Ebola epidemic
Back pain. Muscle aches. Facial flushing. Nasal congestion. Nasopharyngitis (common cold symptoms) Pain in limbs. 1. Headaches. Headaches are a common side effect of oral ED medications, and ...